The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors

被引：156
作者：
Ritter, CA
Arteaga, CL
机构：
[1] Vanderbilt Univ, Sch Med, Div Hematol Oncol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
来源：
SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 01期
关键词：
D O I：
10.1053/sonc.2003.50027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 11
页数：9
相关论文
共 71 条
[1]  
Agus DB, 2000, SEMIN ONCOL, V27, P53
[2]   Development of inhibitors for protein tyrosine kinases [J].
Al-Obeidi, FA ;
Lam, KS .
ONCOGENE, 2000, 19 (49) :5690-5701
[3]   Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].
Albanell, J ;
Rojo, F ;
Averbuch, S ;
Feyereislova, A ;
Mascaro, JM ;
Herbst, R ;
LoRusso, P ;
Rischin, D ;
Sauleda, S ;
Gee, J ;
Nicholson, RI ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124
[4]   ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression [J].
Anderson, NG ;
Ahmad, T ;
Chan, K ;
Dobson, R ;
Bundred, NJ .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) :774-782
[5]  
Arteaga CL, 2001, J CLIN ONCOL, V19, p32S
[6]   The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer [J].
Bartlett, JMS ;
Langdon, SP ;
Simpson, BJB ;
Stewart, M ;
Katsaros, D ;
Sismondi, P ;
Love, S ;
Scott, WN ;
Williams, ARW ;
Lessells, AM ;
Macleod, KG ;
Smyth, JF ;
Miller, WR .
BRITISH JOURNAL OF CANCER, 1996, 73 (03) :301-306
[7]   ZD1839 ('Iressa')1,2 as an anticancer agent [J].
Baselga, J ;
Averbuch, SD .
DRUGS, 2000, 60 (Suppl 1) :33-40
[8]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[9]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[10]   Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer [J].
Baselga, Jose ;
Mendelsohn, John .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1997, 2 (02) :165-174
12345678